Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Saved in:
| Title: | Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. |
|---|---|
| Authors: | Das S; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Ciombor KK; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Haraldsdottir S; Divisions of Medical Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Pumpalova Y; Division of Hospital Medicine, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Sahin IH; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA., Pineda G; Divisions of Medical Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Shyr Y; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Lin EP; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Big Data Research Center, Fu Jen Catholic University, Taipei, Taiwan., Hsu CY; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Chu SK; Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Goff LW; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Cardin DB; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Bilen MA; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA., Fisher GA; Divisions of Medical Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Wu C; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA., Berlin J; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. |
| Source: | The oncologist [Oncologist] 2020 Aug; Vol. 25 (8), pp. 669-679. Date of Electronic Publication: 2020 Jan 14. |
| Publication Type: | Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
